Jiahui Health and IASO Biotechnology have announced a deepening of their strategic collaboration to jointly build a BCMA-targeted CAR-T Equecabtagene Autoleucel Injection treatment centre and further promote the long-term sustainable development of the CAR-T international treatment platform.

Relapsed/refractory multiple myeloma remains a challenging disease necessitating the development of more effective treatment options. In the past decade, myeloma therapies have made significant advancements with the introduction of new treatment modalities. One of the new major targets for these novel therapeutics has been B-cell maturation antigen (BCMA), which is expressed on mature B-lymphocytes and plasma cells. There are three main categories of BCMA-targeted therapies currently available, including bispecific antibodies (BsAbs), antibody drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies.

Jiahui will continue to focus on internationally advanced treatment concepts, medication, and technologies for the benefit of local and foreign patients in China.

Jiahui International Cancer Center has established an international CAR-T treatment team and has successfully carried out treatments in collaboration with various companies, including IASO Biotechnology and Fosun Kite.

Jiahui's CAR-T multidisciplinary treatment team, led by Dr Vicky LEE, Director of the Jiahui International Cancer Center and Chief of Medical Oncology at Jiahui International Cancer Center, has conducted a series of studies in the clinical practice of novel technologies and has successfully developed various international treatments.